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Abstract 
Objectives: Impaired muscle function is common in knee osteoarthritis (OA). Numerous 
biochemical molecules have been implicated in the development of OA; however, these have 
only been identified in the joint and serum. This study compared the expression of interleukin 
(IL-15) and Forkhead box protein-O1 (FoxO1) in muscle of patients with knee OA 
asymptomatic individuals, and examined whether IL-15 was also present in the joint and 
serum.  
Method: Muscle and blood samples were collected from 19 patients with diagnosed knee OA 
and 10 age-matched asymptomatic individuals. Synovial fluid and muscle biopsies were 
collected from the OA group during knee replacement surgery. IL-15 and FoxO1were 
measured in the skeletal muscle.  IL-15 abundance was also analysed in the serum of both 
groups and synovial fluid from the OA group. Knee extensor strength was measured and 
correlated with IL-15 and FoxO1 in the muscle.  
Results:  FoxO1 protein expression was higher (p=0.04), whereas IL-15 expression was 
lower (p=0.02) in the muscle of the OA group. Strength was also lower in the OA group, and 
was inversely correlated with FoxO1 expression. No correlation was found between IL-15 in 
the joint, muscle or serum.  
Conclusion: Skeletal muscle, particularly the quadriceps, is affected in people with knee OA 
where elevated FoxO1 protein expression was associated with reduced muscle strength.  
While IL-15 protein expression in the muscle was lower in the knee OA group, no correlation 
was found between the expression of IL-15 protein in the muscle, joint and serum, which 
suggests that inflammation is regulated differently within these tissues. 
Australian Clinical Trials Registry (ACTR) number: ACTRN12613000467730 
Key words: inflammation, muscle, osteoarthritis, strength  
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Introduction  
Knee osteoarthritis (OA) is a common, progressive and debilitating disease that 
affects the entire joint structure, with increased inflammation evident within the synovial 
membrane and synovial tissues [1]. Recently, we have reported increased inflammation in the 
vastus lateralis muscle of patients with end-stage knee OA [2]. Specifically, we reported 
increased expression of pro-inflammatory cytokines (IL-6, TNF, MCP-1) and signalling 
molecules (STAT3, p65 NF-B and JNK). This inflammatory profile correlated with reduced 
muscle strength and altered walking pattern [3]. This previous work did not compare 
systemic and local inflammation within the synovial fluid of patients with OA.  
Of the possible biomarkers that link the loss of muscular function and synovial fluid 
inflammation, interleukin-15 (IL-15) has emerged as a cytokine of interest.  IL-15 is a T-cell 
growth factor and an anabolic cytokine that is expressed in skeletal muscle tissue [4]. 
Because IL-15 expression is increased with the atrophy associated with aging and muscle 
unloading, it may act to minimise muscle loss [5]. However, it remains unknown whether IL-
15 expression is altered in response to muscle injury or disease such as OA.  
The FoxO family of Forkhead transcription factors is associated with the regulation of 
muscle atrophy and hypertrophy [6]. Elevated levels of FoxO1 gene expression is apparent in 
aging and diabetes and other conditions associated with pronounced muscle wasting [7]. 
However, no studies to date have investigated expression of FoxO1 in skeletal muscle in knee 
OA, where muscle weakness and muscle loss are key features.  
In this study we analyse the abundance of IL-15 in muscle, synovial fluid and serum 
in the people with knee OA and compared FoxO1expression in muscle of patients with knee 
OA and asymptomatic individuals. We also investigated the association between knee 
extensor muscle strength and IL-15 and FoxO1 protein expression in the muscle. 
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Methods 
Participant characteristics 
Nineteen patients (9 males and 10 females) with diagnosed end-stage knee OA and 10 
(3 males and 7 females) age-matched asymptomatic inidividuals participated in the study. 
Patients with knee OA were recruited from the Warringal Private Medical Centre, Melbourne 
if they aged 50 yr and over, and waiting for knee replacement surgery. They were excluded if 
they had a pre-existing neurological or other orthopaedic conditions. Participants from the 
control group were asymptomatic aged 50 and over, had no clinical symptoms of OA, 
rheumatoid arthritis or history of knee trauma or pain, uncontrolled systemic diseases or pre-
existing neurological conditions.  Participants were recruited via advertisement in a local 
newsletter. All participants were informed about the study and signed a consent form. The 
study protocol was approved by the Human Research Ethics Committees of Victoria 
University, La Trobe University and Warringal Private Hospital. 
Procedures 
Participants from both groups were assessed to determine their anthropometric profile 
and knee extensor strength. They also completed questionnaires to assess quality of life and 
physical activity, and provided blood and muscle biopsy samples. Synovial fluid was 
collected from the knee OA group during their knee replacement surgery. Synovial fluid 
could not be collected from the control group due to ethical constraints to avoid the risk of 
damaging the knee joint during this procedure. Participants from the knee OA group also 
completed a questionnaire to assess pain, physical function and joint stiffness approximately 
7-14 days prior to their knee replacement surgery.  
Knee extensor strength 
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The strength of the knee extensor muscle group was measured in the affected leg for 
knee OA and in the control in the leg from which the muscle biopsy was taken. Strength, 
defined as peak torque, was measured using a portable, purpose-built, non-extendable strain 
gauge (load cell) as described previously [2]. The knee strength scores were normalised to the 
participant’s height and body weight to account for differences in body size using the 
formula: 
    
100
)(



nbodyweightmheight
nmstrength
strengthnormalised  
Health related quality of life questionnaires 
Quality of life 
Quality of life was measured using the self-administered Assessment of Quality of 
Life (AQoL) utility instrument, which assesses quality of life over five domains [8]. The 
instrument scores for each dimension and provides an overall utility score range from 0 to 1, 
with 0 representing the worst health and 1 representing perfect health. 
Physical activity 
The incidental and planned activity questionnaire (IPEQ) for elderly people was used 
to assess the physical activity level of the participants [9]. The questionnaire includes 10 
questions that estimate the physical activity during the last week, and cover the frequency and 
duration of planned activity and incidental activities. Total time spent was summed across all 
components and expressed as hours per week as detailed in Delbaere et al. [9].  
Knee pain, function and stiffness 
Physical function, pain and stiffness were assessed only in the knee OA group using 
the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) [10]. This 
index assesses the severity of the knee pain during 5 daily activities (range 0–500), together 
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with stiffness (range 0–200) and the severity of impairment of lower-extremity function 
during 17 activities (0–1700). All three subcategories were summed to give a global 
WOMAC score (range 0–2400). 
Muscle biopsy, synovial fuild and blood collection  
Resting muscle samples were taken from the vastus lateralis. The muscle sample 
from knee OA was collected during their knee replacement surgery approximately 5 cm 
proximal to the suprapatellar pouch as described previously [2]. The biopsies were taken after 
the skin was incised and prior to knee joint capsule incision. This procedure did not cause any 
trauma to the muscle or the joint at that time. Synovial fluid (5 ml) was collected from the 
knee OA group using a syringe and needle during the participants’ knee replacement surgery 
prior to knee joint capsule incision. Insufficient synovial fluid was available to aspirate from 
two patients; therefore the analysis of IL-15 in the synovial fluid is reported for 17 patients. 
Muscle samples from the controls were collected utilising the needle biopsy technique as 
described previously [11]. A blood sample was collected from an antecubital vein after an 
overnight fast of at least 10 hours. Blood was centrifuged and serum was stored at –80°C 
until analysis. 
Protein extraction and immunoblotting 
Approximately 20 mg of skeletal muscle was homogenised in 300 µl of lysis buffer 
(20 mM Tris/HCl, 5 mM EDTA, 10 mM Na4P2O7, 100 mM NaF, 2 mM Na3VO4, 1% 
Nonident P40) containing protease and phosphatase inhibitor cocktails (Sigma-Aldrich, 
Australia)  using the Precellys®24 tissue homgeniser (20 sec, setting 5,500 rpm) (Sapphire 
Bioscience, NSW, Australia) and 1.0 mm zirconia/silica beads (Daintree Scientific, 
Tasmania, Australia). Protein content was determined using the Biorad DC Protein Assay 
(Bio-Rad Laboratories, Hercules, CA). Protein (30 g) was separated by 4-15% SDS-PAGE 
using Criterion TGX precast gels (Bio-Rad Laboratories, Hercules, CA), transferred onto 
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PVDF membranes (Trans-Blot® Turbo™ Transfer System, Bio-Rad Laboratories) and 
blocked with 5% (w/v) bovine serum albumin (BSA; Sigma-Aldrich).  Primary antibodies, 
including pFoxO1 (ser256), FoxO1 (Cell Signaling Technology Inc., Danvers, MA) and 
GAPDH (Sigma-Aldrich), diluted in blocking buffer were applied and incubated overnight at 
4°C.  Membranes were exposed to anti-rabbit HRP-conjugated secondary antibodies (GE 
Healthcare, NSW, Australia) and visualised by enhanced chemiluminescence (Super Signal 
West Femto Maximum Sensitivity Substrate, Thermo-Fisher Scientific, VIC, Australia). 
Images were captured using the Chemidoc MP Imaging system (Bio-Rad Laboratories) and 
the band density was quantified using Image Lab 4.1 software (Bio-Rad Laboratories,). 
Membranes were stripped (Restore Western Blot Stripping Buffer, Thermo-Fisher Scientific) 
before being re-probed for FoxO1 and GAPDH. 
Multiplex Suspension Array System 
Muscle was homogenised in lysis buffer (Millipore, Kilsyth, VIC, Australia) then centrifuged 
at 3,000 rpm for 10 min. Protein content of the supernatant from the muscle homogenate was 
measured using a BCA protein assay (Thermo Fisher Scientific). Serum (25 µl), synovial 
fluid (25 µl) and muscle homogenate supernatant (25 µl) were then added in duplicate to a 
commercial immunoassay (MILLIPLEX® Human Cytokine/Chemokine Magnetic Bead 
Panel) customised for IL-15. Data were analysed on a Luminex 200 System according to 
the manufacturer’s instructions,. The mean fluorescence intensity of each sample was used to 
estimate the concentration of IL-15 against a standard curve.  
RNA Extraction and qPCR   
Total cellular RNA was extracted as previously described [12]. RNA quality and 
concentration were determined using the NanoDrop 1000 Spectrophotometer (Thermo-Fisher 
Scientific, VIC, Australia). First-strand cDNA was generated from 1.0 μg total RNA using 
High Capacity RNA-to-cDNA kit (Applied Biosystems, Foster City, CA). qPCR was 
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performed using BioRad CFX384 PCR system (Bio-Rad Laboratories) and PCR was 
performed in duplicate with reaction volumes of 10 μl, containing SsoAdvanced™ SYBR® 
Green (Bio-Rad Laboratories, Hercules, CA) forward and reverse primers and cDNA 
template (25 ng/l). Data were analyzed using a comparative quantification cycle (Cq) 
method  as described (INSERT: TRENERRY ET AL 2007). The efficacy of TBP as an 
endogenous control was examined using the equation 2
-ΔCq
. No changes in the expression of 
this gene was observed (data not shown) so it was considered an appropriate endogenous 
control for this study. Primers were designed using Primer Express software package version 
3.0 (Applied Biosystems, Foster City, CA). FOXO1 forward: 5’-
CCGAACAGGATGATCTTGGAG; FOXO1 reverse 5’-GCGGGTACACCATAGAATGCA; 
IL-15 forward: 5’-TTTCTAACTGAAGCTGGCATTCAT; IL-15 reverse: 5’-
CCAGTTGGCTTCTGTTTTAGGAA; TBP forward: 5’-
CGAATATAATCCCAAGCGGTTT; TBP reverse 5’-CCGTGGTTCGTGGCTCTCT. 
Statistical analysis 
The distribution of data was assessed for normality and non parametric tests were 
used if normality was not met. Mann-Whitney U tests were used to examine the differences 
between the groups in the protein and gene expression of IL-15 and FoxO1 and knee strength. 
Unpaired t-tests were used to assess the differences between the group demographic (age, 
height, body mass and body mass index (BMI)) and the health related quality of life 
questionnaires. Spearman’s Rho correlation was used to investigate the association between 
IL-15 in the synovial fluid and the expression of IL-15 in the muscle (protein and gene) and 
serum (protein) in the OA group only. The relationship between the knee muscle strength 
(absolute values) and abundance of IL-15 and FoxO1 in the muscle was also investigated in 
the knee OA group. All statistical analyses were performed using IBM SPSS Version 20 
(SPSS Inc, Chicago, IL, USA) and a p value less than 0.05 was considered statistically 
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significant. The values reported for the protein and gene abundance are arbitrary units (A.U) 
and all values are presented as mean ± standard error of the mean (SEM). 
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Results 
The main characteristics of the groups, including health related quality of life 
questionnaires, as well as the self-reported pain, stiffness and function for the OA group, are 
presented in Table 1. Body mass and height were greater in the OA compared with the 
control group (p = 0.02).  
Serum IL-15 concentration was below the detectable threshold of the assay and as 
such, several samples had missing values. Therefore, the data for IL-15 are reported as raw 
mean fluorescent intensity in all tissues (for muscle, serum and synovial fluid) for 
consistency in reporting the results. IL-15 protein expression was significantly lower in the 
vastus lateralis of the OA group compared with the control group (31%, p=0.02, Table 2 
and Figure 1). No correlations were found between IL-15 expression in the synovial fluid, 
muscle and serum. 
FoxO1 protein expression was significantly higher in the OA group compared with 
the control group (44%, p=0.04, Table 2 and Figure 1), whereas there were no significant 
differences for FOXO1 mRNA, or pFoxO1 (ser256) between the groups (Table 2).  
Reduced muscle strength in the knee OA group was significantly correlated with 
higher levels of FoxO1 protein expression in the muscle (r=-0.56, p=0.03).  
 
Discussion 
FoxO1 and IL-15 are both expressed in skeletal muscle and are related to muscle 
atrophy/hypertrophy regulation. In the present study FoxO1 protein expression was higher, 
whereas IL-15 protein expression was lower in the muscle of OA patients compared with 
age-matched control subjects. Quadriceps strength was also lower in the knee OA group, 
which correlated with a higher level of FoxO1 protein expression in the muscle.  
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Furthermore, the level of IL-15 protein appears to be different between the muscle, knee joint 
and serum.  
FoxO1 is a biomarker of age-related muscle atrophy and dysfunction. mRNA 
expression of FoxO1 is higher in older people compared with young people, and is correlated 
with reduced muscle mass [13]. Moreover, the expression and activation of FoxO1 in 
articular cartilage is dysregulated in aging and OA, both in human cartilage and a mouse 
model of OA (surgically-induced OA) [14]. FoxO1 is phosphorylated at several sites by AKT 
to inhibit its transcriptional activity [15].  Despite no differences in phosphorylated (ser256) 
FoxO1 in the present study, people with knee OA demonstrated greater FoxO1 protein 
expression in the vastus lateralis compared to asymptomatic older adults. This greater 
expression of FoxO1 was associated with reduced muscle strength, which may be attributed 
to greater muscle atrophy and impaired muscle function in patients with knee OA.  
IL-15 is a cytokine that promotes skeletal muscle differentiation and hypertrophy in 
vitro [4]. Increased expression of IL-15 mRNA in muscle is evident with aging and limb 
unloading, and may serve to counteract muscle wasting [5]. However, we observed that IL-15 
protein expression in muscle was lower in patients with OA compared to age-matched 
asymptomatic individuals. Moreover, muscle strength did not correlate with the abundance of 
IL-15 in the muscle. IL-15 expression may have been lower in the patients with OA because 
they had end-stage OA, where a muscle loss might be expected. Alternatively, there are 
possibly differences in the aetiology of muscle wasting with OA and local factors that 
influence the activity of IL-15 in muscle.  
Despite the differences in skeletal muscle IL-15 protein abundance between the 
groups, serum IL-15 concentration was similar. IL-15 is mainly implicated in the 
pathophysiology of rheumatoid arthritis [16]. However, a recent study reported higher 
circulating concentration of IL-15 in people with various degrees of knee OA compared with 
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healthy individuals. Yet, it seems that circulating levels of IL-15 might not be consistently 
elevated in people with arthritis (OA and rheumatoid arthritis), and might also be related to 
different stages and severity of the disease [17].  
Synovitis is associated with symptoms and progression of cartilage degeneration, 
where IL-15 is elevated in the synovial fluid in patients with rheumatoid arthritis [18]. The 
inflammatory pathway in knee OA may differ from rheumatoid arthritis (an autoimmune 
disease) as a result of variability of adaptive immune responses in OA [19]. A recent study 
reported higher levels of IL-15 in the synovial fluid in early-stage compared with end-stage 
knee OA [20]. We could not collect synovial fluid from the control group, and therefore we 
could not determine if the concentration of IL-15 in the synovial fluid from the OA patients 
was abnormal. Nevertheless, the lack of any correlation between the IL-15 in the muscle, 
joint and serum suggests that inflammation is differentially regulated within various tissue 
types.  
Conclusion 
Patients with knee OA were characterised by elevated skeletal muscle FoxO1 protein 
and reduced IL-15 protein expression and knee extensor strength. Our current findings 
contribute further to the evidence that skeletal muscle, particularly the quadriceps, is affected 
in people with knee OA, where inflammation and muscle atrophy are associated with loss of 
muscle mass and function. The lack of any correlation between IL-15 protein abundance in 
the muscle, joint and serum suggests that inflammation is differentially regulated within these 
tissues.  
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Table 1: Participant’s demographic  
Parameters Control (n=10) OA (n=19) P value 
Age (yr) 67.4 ± 2.4 66.1 ± 1.2 0.58 
Gender  % (n) 70%(7) F 
30%(3) M 
53%(10) F 
47%(9) M 
 
Height (m) 1.6 ± 0.2 1.7 ± 0.2 0.02* 
Body mass (kg) 74.2 ± 5.8 88.3 ± 3.5  0.02* 
Body mass index  (kg/height
2
) 28.2 ± 1.7 30.3 ± 0.9 0.16 
Health related quality of life questionnaires 
AQoL 0.89 ± 0.03 0.7 ± 0.1 0.29 
IPAQ total 34.2 ± 4.5 38.3 ± 4.3 0.66 
IPAQ incidental 30.5 ± 3.9 32.4 ± 4.1 0.89 
IPAQ planned 3.6 ± 1.1 5.8 ± 1.2 0.25 
WOMAC pain --------------- 305.2 ± 31.5 ----------- 
WOMAC stiffness --------------- 93.0 ± 12.9 ----------- 
WOMAC function --------------- 673.7 ± 80.4 ----------- 
WOMAC total --------------- 1072.0 ± 116.9 ----------- 
Knee strength (%BW *height) 7.2 ± 0.9 5.0 ± 0.4  0.02* 
*Significant level p < 0.05; values are presented as mean ± SEM 
Abbreviation: AQol - Assessment of quality of life; IPAQ- Incidental and Planned Activity 
Questionnaire; WOMAC – Western Ontario and McMaster University Osteoarthritis Index 
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Table 2: FoxO1 and IL-15 mRNA and protein expression in skeletal muscle, serum and 
synovial fluid 
 Control (n=10) Knee OA (n=19) P value 
Inflammatory markers in the muscle 
FoxO1 mRNA  12.91 ± 2.5 14.82 ± 2.7 0.69 
FoxO1 total protein  0.24 ± 0.03 0.45 ± 0.05 0.04* 
FoxO1 phosphorylated (ser256) 0.70 ± 0.1 0.89 ± 0.1 0.65 
pFoxO1:FoxO1  3.30 ± 0.7 2.33 ± 0.4 0.12 
IL-15 mRNA  0.39 ± 0.04 0.70 ± 0.27 0.37 
IL-15 protein  167.85 ± 19.8 111.14 ± 9.9 0.02* 
Inflammatory marker in the serum 
IL-15 protein  31.52 ± 5.0 28.30 ± 3.2 0.19 
Inflammatory marker in the synovial fluid 
IL-15 protein†  --------------- 144.47 ± 9.0 --------------- 
*Significant at p<0.05; values are presented as mean ± SEM. All values are presented as 
arbitrary units.  
†The data reported for IL-15 in the synovial fluid are from n=17. 
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Figure 1: FoxO1 and IL-15 mRNA and protein expression in skeletal muscle, serum and 
synovial fluid 
 
Figure legend: Means are normalised to GAPDH (immunoblotting) or TBP (qPCR) and 
values are presented as mean ± SEM. The sample size reported for IL-15 for the OA group is 
17, for all other variables is as follows: OA (n=19), Control (n=10). All values are presented 
as arbitrary units. *Significantly different to control at p<0.05.  
 
